Julia Alcaide

First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: Phase II randomised MACRO2 TTD study

Enrique Aranda, Pilar García‐Alfonso, Manuel Benavides et al. · European Journal of Cancer · 2018 · 78 citations

Phase Ii, Macro2 Ttd Study, First-line Mfolfox +9

Role of clinical pharmacists to prevent drug interactions in cancer outpatients: a single-centre experience

C. López-Martín, Margarita Garrido Siles, Julia Alcaide et al. · International Journal of Clinical Pharmacy · 2014 · 76 citations

Drug Interactions, Clinical Pharmacists, Medicine +7

Final overall survival for the phase III KN177 study: Pembrolizumab versus chemotherapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC).

Thierry André, Kai‐Keen Shiu, Tae Won Kim et al. · Journal of Clinical Oncology · 2021 · 72 citations

Cancer Management, Immunology, Pathology +20

Pembrolizumab versus chemotherapy in microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer: 5-year follow-up from the randomized phase III KEYNOTE-177 study

Thierry André, Kai Keen Shiu, Tae Won Kim et al. · Annals of Oncology · 2024 · 65 citations · Full text

Alterations of perineuronal nets in the dorsolateral prefrontal cortex of neuropsychiatric patients

Julia Alcaide, Ramón Guirado, Carlos Crespo et al. · International Journal of Bipolar Disorders · 2019 · 48 citations · Full text